Yanhui Ma

Part of Johnson & Johnson, LXN Corp is a company that develops and commercializes fructosamine monitoring technology for diabetes. The company is based in San Diego, CA. The company was founded by John F. Burd. LXN was acquired by Inverness Medical Technology, Inc. on March 29, 2001 for $18.48 million.

ChemBridge Corp. is a private company that engages in the research, development, and production of chemical products. The company is based in San Diego, CA. The company was founded by Nelson L. Levy.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Part of Resonac Holdings Corp., MAST Immunosystems, Inc. is a company that specializes in providing quality allergy care through their comprehensive panel test for environmental and food allergens called OPTIGEN® Allergen-Specific IgE Assay. The company is based in Mountain View, CA. The company also offers the OPTIGEN® Multiplex Allergen-Specific IgE Assay and the AP3600™ Fully-Automated System for OPTIGEN Allergy. MAST Immunosystems was acquired by Resonac Corp., part of Resonac Holdings Corp. from April 20, 2020 on November 04, 1996 for $40 million.

Part of Medtronic Plc, Novacor, Inc. is an American company that develops artificial heart and related technologies. The company is based in CA. Novacor was acquired by World Heart Corp., a subsidiary of Medtronic Plc from Edwards Lifesciences Corp. on June 30, 2000 for $58 million.

Mercator MedSystems, Inc. develops medical injection devices. The firm focuses on the treatment of peripheral artery disease using its catheter-guided, micro-infusion systems for site-specific, non-systemic delivery of therapeutic agents directly across any blood vessel. It offers bullfrog micro-infusion device and blowfish trans-bronchial micro-infusion device. The company was founded by Kirk Patrick Seward, Michael Vestel, and Albert P. Pisano in 2000 and is headquartered in Emeryville, CA.

zuChem, Inc. manufactures and supplies glycochemicals for the pharmaceutical, food and related industries. Its products include natural polyols, rare sugars and carbohydrates. Its glycochemicals are key components of many drugs and drug candidates as well as many specialty food ingredients. The company was founded by David C. Demirjian in 2001 and is headquartered in Chicago, IL.

Advanced Medical Technology Association is a trade association which provides medical technology solutions. The company was founded in 1974 and is headquartered in Washington, DC.

Etubics Corp. develops commercial prophylactic vaccines and immunotherapy products. It offers proprietary immunization platform technology called the etubics platform that develops therapeutic vaccines for colon and breast cancers and preventative vaccines for H1N1 Influenza and HIV. The company was founded by Frank R. Jones in 2003 and is headquartered in Seattle, WA.

Medisync Midwest LLC provides consultation services. It offers practice management partnership, clinical research, volume to value planning, diagnostic assessments, and HCC program. The company is headquartered in Cincinnati, OH.

International Opera Alliance is an entertainment company focused on musical and arts activities. The company is headquartered in Fairfax, VA.

OHK Medical Devices, Inc. develops and manufactures self-contained, sterile, exsanguinating tourniquet products. Its products include hand and wrist, foot and ankle, upper extremity, lower extremity and pediatrics. The company was founded by Noam Gavriely in 1999 and is headquartered in Grandville, MI.

Hadean Ventures AS (Hadean Ventures) is a venture capital firm that manages alternative investment funds. The firm was founded by Ingrid Helene Teigland Akay in 2014 and is headquartered in Oslo, Norway.

Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada.

Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation.